Article By:
ChinaBio® Today
Saturday, July 8, 2023 2:18 PM EDT
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic therapy developed by VBI Vaccines for $15 million.